Terms ending in 2039
Every in-force patent on Kymab Limited's record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,440,960 | Tigit Antibodies. Encoding Nucleic Acids and Methods of Using Said Antibodies in Vivo In force · High confidence | Kymab Limited | In force | High confidence | |
| US 11,680,101 | Anti-Opg Antibodies In force · High confidence | Kymab Limited | In force | High confidence | |
| US 11,919,969 | Bispecific Antibodies for Factor IX and Factor X In force · High confidence | Kymab Limited | In force | High confidence | |
| US 11,878,048 | Use of the Extracellular Domain of Transferrin Receptor 2 for the Diagnosis and Treatment of Primary or Secondary Sclerosing Diseases In force · High confidence | Kymab Limited | In force | High confidence | |
| US 10,815,308 | Fixaxfx Bispecific Antibody with Common Light Chain In force · High confidence | Kymab Limited | In force | High confidence | |
| US 12,723,104 | Improved Lambda Antibodies In force · High confidence | Kymab Limited | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.